Safety and Immunogenicity of an Inactivated Influenza A/H5N1 Vaccine Given with or without Aluminum Hydroxide to Healthy Adults: Results of a Phase I–II Randomized Clinical Trial | Zendy

Wendy A. Keitel | Zendy; James Campbell | Zendy; John J. Treanor | Zendy; Emmanuel B. Walter | Zendy; Shital M. Patel | Zendy; Fenhua He | Zendy; Diana L. Noah | Zendy; Heather Hill | Zendy

Open Access

Safety and Immunogenicity of an Inactivated Influenza A/H5N1 Vaccine Given with or without Aluminum Hydroxide to Healthy Adults: Results of a Phase I–II Randomized Clinical Trial

Author(s) -

Wendy A. Keitel,

James Campbell,

John J. Treanor,

Emmanuel B. Walter,

Shital M. Patel,

Fenhua He,

Diana L. Noah,

Heather Hill

Publication year - 2008

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/592172

Subject(s) - immunogenicity , influenza a virus subtype h5n1 , virology , medicine , influenza vaccine , phase (matter) , clinical trial , randomized controlled trial , hydroxide , microbiology and biotechnology , immunology , vaccination , biology , antibody , chemistry , virus , organic chemistry

Dose-sparing strategies are being explored for vaccines against pandemic influenza. We evaluated the dose-sparing potential of aluminum hydroxide (AlOH) adjuvant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research